A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).

ABSTRACT:

Background

The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab improves lung function in patients with moderate-to-severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed to assess lebrikizumab's effect on eosinophilic inflammation and remodelling.

Objective

To report safety and efficacy results from enrolled participants with available data from CLAVIER.

Methods

We performed bronchoscopy on patients with uncontrolled asthma before and after 12 weeks of randomized double-blinded treatment with lebrikizumab (n = 31) or placebo (n = 33). The pre-specified primary end-point was relative change in airway subepithelial eosinophils per mm² of basement membrane (cells/mm² ). Pre-s

SUBMITTER: Austin CD 

PROVIDER: S-EPMC7756263 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature